U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07827612) titled 'A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer' on Sept. 15.
Brief Summary: The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC). Safety tests will also be conducted.
For each participant, the study will last up to 5 years.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Urinary Bladder Neoplasms
Urologic Neoplasms
Receptor, Fibroblast Growth Factor, Type 3
Intervention: ...